Cargando…

Cardiovascular outcomes among HIV-infected veterans receiving atazanavir

OBJECTIVE: Patients with HIV infection have an increased risk of cardiovascular disease compared with uninfected individuals. Antiretroviral therapy with atazanavir (ATV) delays progression of atherosclerosis markers; whether this reduces cardiovascular disease event risk compared with other antiret...

Descripción completa

Detalles Bibliográficos
Autores principales:	LaFleur, Joanne, Bress, Adam P., Rosenblatt, Lisa, Crook, Jacob, Sax, Paul E., Myers, Joel, Ritchings, Corey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603981/ https://www.ncbi.nlm.nih.gov/pubmed/28692532 http://dx.doi.org/10.1097/QAD.0000000000001594

Ejemplares similares

Tenofovir-Associated Bone Adverse Outcomes among a US National Historical Cohort of HIV-Infected Veterans: Risk Modification by Concomitant Antiretrovirals
por: LaFleur, Joanne, et al.
Publicado: (2018)

Atazanavir and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Patients: A Systematic Review
por: Chow, Dominic, et al.
Publicado: (2016)

Risk of cardiovascular events among patients with HIV treated with atazanavir-containing regimens: a retrospective cohort study
por: Rosenblatt, Lisa, et al.
Publicado: (2016)

No difference in persistence to treatment with atazanavir or darunavir in HIV patients in a real-world setting
por: Farr, Amanda M, et al.
Publicado: (2014)

Health Care Costs in a Cohort of HIV-Infected U.S. Veterans Receiving Regimens Containing Tenofovir Disoproxil Fumarate/Emtricitabine
por: Nelson, Richard E., et al.
Publicado: (2018)

Angina Severity, Mortality, and Healthcare Utilization Among Veterans With Stable Angina
por: Owlia, Mina, et al.
Publicado: (2019)

1572 Impact of Hyperbilirubinemia on Persistence and Adherence of Atazanavir among HIV Patients
por: Rosenblatt, Lisa, et al.
Publicado: (2014)

Erratum to: Risk of cardiovascular events among patients with HIV treated with atazanavircontaining regimens: a retrospective cohort study
por: Rosenblatt, Lisa, et al.
Publicado: (2016)

Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir
por: Beckman, Joshua A., et al.
Publicado: (2017)

External Validation of the Bilirubin–Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients
por: Rekić, Dinko, et al.
Publicado: (2012)

Role of atazanavir in the treatment of HIV infection
por: Rivas, Pablo, et al.
Publicado: (2009)

Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial(§)
por: Gallant, Joel, et al.
Publicado: (2017)

Association Between Atazanavir‐Induced Hyperbilirubinemia and Cardiovascular Disease in Patients Infected with HIV
por: Li, Michael, et al.
Publicado: (2020)

Correlates of Initiation of Treatment for Chronic Hepatitis C Infection in United States Veterans, 2004–2009
por: Gundlapalli, Adi V., et al.
Publicado: (2015)

Systematic Literature Review and Meta-Analysis of Renal Function in Human Immunodeficiency Virus (HIV)-Infected Patients Treated with Atazanavir (ATV)-Based Regimens
por: Cure, Sandrine, et al.
Publicado: (2015)

Atazanavir nephrotoxicity
por: Hara, Masaki, et al.
Publicado: (2015)

Metabolic and Kidney Disorders Correlate with High Atazanavir Concentrations in HIV-Infected Patients: Is It Time to Revise Atazanavir Dosages?
por: Gervasoni, Cristina, et al.
Publicado: (2015)

Antenatal Atazanavir: A Retrospective Analysis of Pregnancies Exposed to Atazanavir
por: Samuel, Miriam, et al.
Publicado: (2014)

Predicting poor adherence to antiretroviral therapy among treatment-naïve veterans infected with human immunodeficiency virus
por: Cheng, Yan, et al.
Publicado: (2018)

Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial
por: Restelli, Umberto, et al.
Publicado: (2017)

Adherence and virologic outcomes among treatment-naïve veteran patients with human immunodeficiency virus type 1 infection
por: Cheng, Yan, et al.
Publicado: (2018)

Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial
por: Restelli, Umberto, et al.
Publicado: (2017)

Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial [Corrigendum]
Publicado: (2017)

Evaluating the Relationship Between Diabetes Treatment and Health Care Costs - Measuring the Atom With a Yardstick?
por: LaFleur, Joanne
Publicado: (2005)

Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir
por: Robertson, Kevin, et al.
Publicado: (2018)

Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir
por: Overton, T, et al.
Publicado: (2010)

Factors involved in treatment durability and immunological recovery in a cohort of HIV-positive patients receiving atazanavir-based regimens
por: Giacomelli, Andrea, et al.
Publicado: (2014)

Comparative Assessment of the Magnitude of Hyperlipidemia in HIV-Infected Patients Receiving Lopinavir/r- and Atazanavir/r-Based Antiretroviral Drugs
por: Muya, Esther, et al.
Publicado: (2019)

Long-term treatment of patients with HIV-1: the role of atazanavir
por: Artacho, Miguel Ángel, et al.
Publicado: (2010)

High rates of early treatment discontinuation in hepatitis C-infected US veterans
por: LaFleur, Joanne, et al.
Publicado: (2014)

Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover Study
por: Wongprikorn, Asita, et al.
Publicado: (2016)

Association between the UGT1A1*28 allele and hyperbilirubinemia in HIV-positive patients receiving atazanavir: a meta-analysis
por: Du, Pengqiang, et al.
Publicado: (2019)

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers
por: Dickinson, Laura, et al.
Publicado: (2009)

Pharmacologic Boosting of Atazanavir in Maintenance HIV-1 Therapy: The COREYA Propensity-Score Adjusted Study
por: Hocqueloux, Laurent, et al.
Publicado: (2012)

Safety and efficacy of ombitasvir – 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens
por: Eron, Joseph J, et al.
Publicado: (2014)

Lopinavir to atazanavir or darunavir switch in HIV-1-infected patients with dyslipidemia: an observational study
por: Le Moal, G, et al.
Publicado: (2010)

Therapeutic drug monitoring (TDM) of atazanavir in pregnancy
por: Else, LJ, et al.
Publicado: (2010)

Effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover study
por: Srichatrapimuk, Sirawat, et al.
Publicado: (2023)

Comparison of oxidative stress markers in HIV-infected patients on efavirenz or atazanavir/ritonavir-based therapy
por: Estrada, Vicente, et al.
Publicado: (2014)

Acute development of Cushing syndrome in an HIV-infected child on atazanavir/ritonavir based antiretroviral therapy
por: Dubrocq, Gueorgui, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gubo0alerjgtlvoqq3ldml2gk5